Efficacy and Safety of Gantenerumab in Patients With Alzheimer Disease: A Systematic Review and Meta-analysis
In conclusion, patients with Alzheimer disease treated with gantenerumab showed significant improvement in the ADAS score, FAQ score, hippocampal volume, and CSF biomarkers compared with those treated with placebo. However, the use of gantenerumab is associated with a higher incidence of ARIA-E and ARIA-H.
Authors
- Sai Santhosha Mrudula Alla
- Roohi Kolte (ORCID: https://orcid.org/0000-0002-2523-5776)
- Dhruv Jayeshkumar Shah (ORCID: https://orcid.org/0009-0008-6696-7704)
- Arghadip Das (ORCID: https://orcid.org/0000-0001-7617-7337)
- Noel Emmanuel (ORCID: https://orcid.org/0009-0001-2488-0781)
- Raman Dugyala (ORCID: https://orcid.org/0000-0001-9413-1703)
- Sara Siddiqui (ORCID: https://orcid.org/0000-0003-3942-1593)
- Deekshitha Alla (ORCID: https://orcid.org/0000-0003-4234-6141)
- Rakshna Ramsundar
- Nitheesha Reddy Marepalli
- Aparna Malireddi
- Adithya Andanappa
Institutions
- Andhra University (IN)
- Deccan College of Medical Sciences (IN)
- Gandhi Medical College & Hospital (IN)
- Nil Ratan Sircar Medical College and Hospital (IN)
- Massachusetts College of Pharmacy and Health Sciences (US)
- Sri Ramachandra Institute of Higher Education and Research (IN)
- University of Maroua (CM)
- Symbiosis International University (IN)
- Mysore Medical College (IN)
- Institute of Medical Sciences (IN)
- Medical College and Hospital, Kolkata (IN)
Publication Details
- Journal
- Clinical Neuropharmacology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1097/wnf.0000000000000661
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00